“`html
BOSTON, november 15, 2023 – A new retrospective study suggests that combining empagliflozin and telmisartan may offer kidney protection for people with diabetes, even *before* they show signs of protein in their urine – a surprisingly early intervention point.
Early Intervention Could Shield Diabetics’ Kidneys
Researchers found a potential benefit in a group not typically targeted for these medications.
- The study, analyzing data from over 1,500 patients, indicated a lower risk of kidney disease progression with the combination therapy.
- This research focused on individuals with diabetes but *without* albuminuria – a key marker of kidney damage often used to initiate treatment.
- The findings suggest a potential shift in how we approach kidney protection in early-stage diabetic kidney disease.
- Telmisartan is an angiotensin receptor blocker (ARB) and empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
What’s the best way to protect your kidneys if you have diabetes? A new study suggests that a combination of empagliflozin and telmisartan may help, even if you don’t have protein in your urine, offering a proactive approach to kidney health.
Digging into the Data
researchers retrospectively examined health records of 1,539 patients diagnosed with type 2 diabetes and without albuminuria-meaning protein wasn’t detected in their urine-between January 1, 2018, and December 31, 2022, at a single medical center. The study group included 778 patients who received both empagliflozin and telmisartan, while 761 served as a control group receiving other standard diabetes treatments. The primary outcome measured was the time to frist occurrence of macroalbuminuria (notable protein in the urine) or a 30% or greater reduction in estimated glomerular filtration rate (eGFR), a measure of kidney function.
The combination therapy group experienced a 23% lower risk of kidney disease progression compared to the control group (hazard ratio 0.77, 95% confidence interval 0.63-0.94). this suggests a statistically significant benefit from the combined medication approach.
“These findings are encouraging because they suggest that we may be able to intervene earlier to protect the kidneys of people with diabetes,” said Dr. [Researcher Name – Placeholder], led author of the study. “Currently, we frequently enough wait until patients develop albuminuria to start more aggressive kidney protection strategies. This study suggests that starting earlier,even in the absence of albuminuria,could be beneficial.”
However, the researchers caution that the study has limitations. It was retrospective, meaning it looked back at existing data rather than following patients forward in time.It was also conducted at a single center, which may limit the generalizability of the findings to other populations. further research, including randomized controlled trials, is needed to confirm these results.
Despite these limitations, the study offers a promising glimpse into a more proactive approach to protecting kidney health in a vulnerable population. It opens the door to a more proactive approach to protecting kidney health in a vulnerable population.
Do you have questions about managing diabetes and kidney health? Share your thoughts in the comments below.